Search
Obiltoxaximab
go.drugbank.com/drugs/DB05336ApprovedObiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. … Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin.
Categories: Antiinfectives for Systemic UseNeon
go.drugbank.com/drugs/DB11589ApprovedNeon may be used in the clinical setting as a diagnostic tracer gas in a gas analyzer for a lung diffusion test. … Neon is a chemical element with a chemical symbol Ne and atomic number 10. It is a noble gas that is colorless, odorless, inert and monatomic.
Nandrolone decanoate
go.drugbank.com/drugs/DB08804ApprovedIllicitInvestigational[A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesmRNA-1010
go.drugbank.com/drugs/DB22484ApprovedMFLUSIVA (influenza vaccine, mRNA), also known by its development code mRNA-1010, is a messenger RNA–based vaccine for active immunization against seasonal influenza. … [L64058] Each dose contains three mRNAs encapsulated in lipid nanoparticles, each encoding the hemagglutinin (HA) glycoprotein of one influenza strain recommended for the season; after intramuscular injection
Frovatriptan
go.drugbank.com/drugs/DB00998ApprovedFrovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation.
Prazosin
go.drugbank.com/drugs/DB00457ApprovedInvestigationalPrazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.
Categories: Antihypertensive Agents Indicated for HypertensionDesmopressin
go.drugbank.com/drugs/DB00035ApprovedInvestigationalOn January 15, 2026, the FDA approved a new low-dose sublingual film formulation specifically for the treatment of nocturia in patients at high risk for fluid overload, utilizing a specialized delivery … Additionally, it serves as a critical hematologic agent for the management of mild hemophilia A and von Willebrand disease (Type I) by transiently increasing levels of clotting factors [A31662, A275458
Products: MINIRIN Oral Lyophilisate for sublingual 60mcg, MINIRIN Oral Lyophilisate for sublingual 120mcgTannic acid
go.drugbank.com/drugs/DB09372ApprovedInvestigationalTannic acid is a polyphenolic compound. It is a type of the commercially available tannins. It acts as a weak acid. … Nowadays, tannic acid is applied topically for the treatment of cold sores, diaper rash, fever blisters and poison ivy.
Categories: Compounds used in a research, industrial, or household settingPimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigational[L48241,A232573] Pimavanserin was also under review as a potential treatment for dementia-related psychosis; however, as of April 2021, FDA approval has not been granted for this indication despite previous … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized
Sonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigational[A275521,A275522] On May 13, 2026, the FDA granted accelerated approval to sonrotoclax for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior … [L56193,A275521] Sonrotoclax was rationally designed as a BH3 mimetic with a shallow and broad interaction with the P2 pocket of BCL-2, achieved through a novel 7-azaspiro[3.5]nonane linker; this binding